ClinicalTrials.gg
CompletedNCT06103877Updated Jan 27, 2026

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

A Phase 1 interventional study of AZD1163 and Placebo in Healthy Volunteers, sponsored by AstraZeneca. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Arthritis, Rheumatoid by AstraZeneca — 4 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · AstraZeneca.

Enrollment
21st of 45
108 · median 72
Started
2023
with 1 other
Phase 1
22 of 49
2 open now
Registered
45th of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, this one is the 21st largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2023, is one of 22 in phase 1, and was the 45th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 49 studies in Arthritis, Rheumatoid by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by AstraZeneca, or all of them as a file.
02

Study summary

A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants.

Read the detailed description

This is a first time in human (FTiH), placebo-controlled, sequential study in healthy participants. This study consists of two parts: Part 1 Single Ascending Dose (SAD) and Part 2 Multiple Ascending Dose (MAD). Part 1 will contain 9 cohorts, 8 intravenously (IV) administered dose levels and 1 subcutaneously (SC) administered dose level of AZD1163. Part 2 will contain 2 SC dose levels of AZD1163. A sentinel dosing approach will be taken. Each participant will be involved in the study for approximately 70 weeks.

The study will comprise of:

  • A Screening Period of maximum 28 days for both Part 1 and Part 2.
  • Part 1: A single dose of AZD1163 with an in-clinic period of 7 to 8 days.
  • Part 2: Two doses of AZD1163, given 2 weeks apart both with an in-clinic period of 7 to 8 days.
  • An outpatient Follow-up Period of approximately 15 months.
03

Conditions studied

  • Healthy Volunteers

Keywords

  • Rheumatoid arthritis
  • Pharmocokinetics
  • Healthy volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants with suitable veins for cannulation or repeated venipuncture
  • All females must have a negative pregnancy test
  • Females of must not be lactating and, if heterosexually active, agree to taking approved method/s of
  • between 18 and 32 kg/m\^2 and weigh at least 45 kg

Exclusion criteria

Exclusion Criteria:

  • Has received another new chemical entity
  • History of any disease or disorder which may put participant at risk in the study
  • Current or recurrent disease of clinical significance
  • Medical history of except for cervical carcinoma and non-melanoma skin cancer (NMSC)
  • Any illness, medical/procedure, or trauma
  • Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis result at screening
  • Any positive result on screening for serum surface antigen (HbsAg), hepatitis B core antibody (HbcAb), virus (HCV) antibody, or (HIV)
  • History of latent or active tuberculosis (TB) or exposure to endemic areas
  • Evidence of active TB or untreated/inadequately/inappropriately treated for latent TB
  • Positive testing for Covid-19 prior to dosing, case of Covid-19 within 4 weeks, or long-term Covid-19-related sequelae
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing or presence of fever
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead (ECG), and any clinically important abnormalities in the 12-lead ECG
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Active comparator
    Part 1 Cohort 1 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 2 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 3 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 4 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 5a SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 5b SAD

    Participants will receive SC injection of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 6 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 7 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Active comparator
    Part 1 Cohort 8 SAD

    Participants will receive IV infusion of AZD1163 on Day 1.

    Biological: AZD1163

  • Placebo comparator
    Part 1 Pooled Placebo SAD IV

    Participants will receive matching IV infusion of placebo on Day 1.

    Other: Placebo

  • Placebo comparator
    Part 1 Placebo SAD SC

    Participants will receive matching SC injection of placebo on Day 1.

    Other: Placebo

  • Active comparator
    Part 1 Cohort 9 SAD (Chinese Participants)

    Participants will receive SC injection of AZD1163 on Day 1.

    Biological: AZD1163

  • Placebo comparator
    Part 1 Placebo SAD (Chinese Participants)

    Participants will receive matching SC injection of placebo on Day 1.

    Other: Placebo

  • Active comparator
    Part 2 Cohort 1 MAD (Global)

    Participants will receive SC injection of AZD1163 on Days 1 and 15.

    Biological: AZD1163

  • Active comparator
    Part 2 Cohort 2 MAD (Global)

    Participants will receive SC injection of AZD1163 on Days 1 and 15.

    Biological: AZD1163

  • Placebo comparator
    Part 2 Placebo MAD (Global)

    Participants will receive matching SC injection of placebo on Days 1 and 15.

    Other: Placebo

  • Active comparator
    Part 2 Cohort 3 MAD (Chinese Participants)

    Participants will receive SC injection of AZD1163 on Days 1 and 15.

    Biological: AZD1163

  • Active comparator
    Part 2 Cohort 4 MAD (Japanese participants)

    Participants will receive SC injection of AZD1163 on Days 1 and 15.

    Biological: AZD1163

  • Placebo comparator
    Part 2 Placebo MAD (Chinese participants)

    Participants will receive matching SC injection of placebo on Days 1 and 15.

    Other: Placebo

  • Placebo comparator
    Part 2 Placebo MAD (Japanese participants)

    Participants will receive matching SC injection of placebo on Days 1 and 15.

    Other: Placebo

Interventions

  • BiologicalAZD1163

    In Part 1, Participants will receive AZD1163 through IV infusion or SC injection on Day 1. In Part 2, participants will receive AZD1163 through SC injection on Days 1 and 15.

  • OtherPlacebo

    In Part 1, Participants will receive matching placebo through IV infusion or SC injection on Day 1. In Part 2, participants will receive matching placebo through SC injection on Days 1 and 15.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of single and multiple ascending doses of AZD1163 following IV or SC administration.

    Time frame: From Day -1 until end of study (Day 450)

Secondary outcomes

  1. Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)

    To characterize the pharmacokinetics (PK) of AZD1163 following IV/SC administration of single and multiple ascending doses.

    Time frame: Part 1: Days 1-8, 11, 15, 22, 29, 57, 113, 225, 281, 365, 450; Part 2: Days 1-8, 11, 15-16, 22, 29, 57, 113, 225, 281, 365, 450

  2. Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)

    To characterize the PK of AZD1163 following IV/SC administration of single and multiple ascending doses.

    Time frame: Part 1: Days 1-8, 11, 15, 22, 29, 57, 113, 225, 281, 365, 450; Part 2: Days 1-8, 11, 15-16, 22, 29, 57, 113, 225, 281, 365, 450

  3. Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    To characterize the PK of AZD1163 following SC administration of single and multiple ascending doses.

    Time frame: Part 1: Days 1-8, 11, 15, 22, 29, 57, 113, 225, 281, 365, 450; Part 2: Days 1-8, 11, 15-16, 22, 29, 57, 113, 225, 281, 365, 450

  4. Volume of distribution (apparent) at steady state following extravascular administration (Vz/F)

    To characterize the PK of AZD1163 following SC administration of single and multiple ascending doses.

    Time frame: Part 1: Days 1-8, 11, 15, 22, 29, 57, 113, 225, 281, 365, 450; Part 2: Days 1-8, 11, 15-16, 22, 29, 57, 113, 225, 281, 365, 450

  5. Maximum observed plasma (peak) drug concentration (Cmax)

    To characterize the PK of AZD1163 following IV/SC administration of single and multiple ascending doses.

    Time frame: Part 1: Days 1-8, 11, 15, 22, 29, 57, 113, 225, 281, 365, 450; Part 2: Days 1-8, 11, 15-16, 22, 29, 57, 113, 225, 281, 365, 450

  6. Number of participants with positive anti-AZD1163 antibodies

    To evaluate the immunogenicity of AZD1163.

    Time frame: Part 1: Day 1, 11, 29, 113, 225, 281, 365, 450; Part 2: Day 1, 15, 29, 57, 113, 281, 365, 450

07

Study locations

3 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
  • Research Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2026, 26 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 26 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Nov 1, 2023
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06103877
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Nov 1, 2023
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Jan 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion